Clinical Trial

KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated October 8, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
A Study of Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Subjects with Systemic Sclerosis
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-05-01; most recent amendment 2025-10-06.
Status change: Recruiting → Active, Not Recruiting 2025-10-06
Status change: Not Yet Recruiting → Recruiting 2024-08-13
Trial Details
NCT Number NCT06400303
Lead Sponsor Kyverna Therapeutics
Conditions Systemic Sclerosis, Systemic Sclerosis - Diffuse Cutaneous, Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria
Enrollment 3 participants
Start Date 2024-08-06
Primary Completion 2026-03 (estimated)
Study Completion 2027-03 (estimated)
Updated on ClinicalTrials.gov 2025-10-08